This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cahlin, C. Articles by Lundholm, K. Search for Related Content PubMed PubMed Citation Articles by Cahlin, C. Articles by Lundholm, K.

Effect of Cyclooxygenase and Nitric Oxide Synthase Inhibitors on Tumor Growth in Mouse Tumor Models with and without Cancer Cachexia Related to Prostanoids¹

Surgical Metabolic Research Laboratory at Lundberg Laboratory for Cancer Research, Department of Surgery, Sahlgrenska University Hospital, S-413 45 Göteborg, Sweden

The potential interaction between cyclooxygenase (Cox) and NO metabolic pathways in the control of local tumor growth was evaluated. Mice bearing either a sarcoma-derived tumor (C57Bl; MCG 101) or a malignant melanoma (C3H/HeN; K1735-M2) were used. These models were principally different because they demonstrate, in tumor hosts, conditions with and without cancer cachexia, seemingly related to high and low production of prostanoids, respectively. Cox inhibitors (Cox-1 and Cox-2) decreased tumor growth by 35–40% in MCG 101-bearing mice but had no such effect on melanoma-bearing mice, despite the expression of the Cox-2 protein in melanoma cells. Indomethacin reduced prostanoid production in both tumor (MCG 101) and host tissues and reduced tumor cell proliferation, mainly in vivo. Nitric oxide synthase (NOS) inhibitors (N-nitro-L-arginine methyl ester and N-nitro-L-arginine) reduced tumor growth in vivo by 50% in both tumor models. Tumor growth reduction, related to NOS inhibition, was unrelated to prostanoid production and was an in vivo phenomenon in both tumor models. Specific inhibitors of inducible NOS activity, unexpectedly, had no effect in any tumor model, although inducible NOS protein was present in tumor tissues in large amounts. A combination of Cox and NOS inhibitors had no additive effect on tumor growth (MCG 101). Cox inhibition increased tumor tissue (MCG 101) expression of cNOS mRNA but had no significant effect on tumor tissue expression of the transferrin receptor, vascular endothelial growth factor, or basic fibroblast growth factor. NOS inhibition increased tumor tissue content of cNOS mRNA but showed as well a trend to increase mRNA content of the transferrin receptor and vascular endothelial growth factor. Our results suggest that NOS inhibitors can decrease the local growth of tumors that are either responsive or unresponsive to Cox inhibition. This effect may reflect cross-talk between Cox and NOS pathways within or among tumor cells, or it may represent unrelated effects on tumor and host cells. Whether NO inhibition may be used therapeutically in clinical tumors that are unresponsive to eicosanoid intervention remains to be evaluated.

This article has been cited by other articles:

				E. R. Camp, A. Yang, W. Liu, F. Fan, R. Somcio, D. J. Hicklin, and L. M. Ellis Roles of Nitric Oxide Synthase Inhibition and Vascular Endothelial Growth Factor Receptor-2 Inhibition on Vascular Morphology and Function in an In vivo Model of Pancreatic Cancer Clin. Cancer Res., April 15, 2006; 12(8): 2628 - 2633. [Abstract] [Full Text] [PDF]

				W. Lu and A. J. Schroit Vascularization of Melanoma by Mobilization and Remodeling of Preexisting Latent Vessels to Patency Cancer Res., February 1, 2005; 65(3): 913 - 918. [Abstract] [Full Text] [PDF]

				S. Galli, M. I. Labato, E. Bal de Kier Joffe, M. C. Carreras, and J. J. Poderoso Decreased Mitochondrial Nitric Oxide Synthase Activity and Hydrogen Peroxide Relate Persistent Tumoral Proliferation to Embryonic Behavior Cancer Res., October 1, 2003; 63(19): 6370 - 6377. [Abstract] [Full Text] [PDF]

				D. O. McCarthy Rethinking Nutritional Support for Persons with Cancer Cachexia Biol Res Nurs, July 1, 2003; 5(1): 3 - 17. [Abstract] [PDF]

				C. Denkert, M. Köbel, S. Berger, A. Siegert, A. Leclere, U. Trefzer, and S. Hauptmann Expression of Cyclooxygenase 2 in Human Malignant Melanoma Cancer Res., January 1, 2001; 61(1): 303 - 308. [Abstract] [Full Text]

				C. Cahlin, A. Körner, H. Axelsson, W. Wang, K. Lundholm, and E. Svanberg Experimental Cancer Cachexia: The Role of Host-derived Cytokines Interleukin (IL)-6, IL-12, Interferon-{{gamma}}, and Tumor Necrosis Factor {{alpha}} Evaluated in Gene Knockout, Tumor-bearing Mice on C57 Bl Background and Eicosanoid-dependent Cachexia Cancer Res., October 1, 2000; 60(19): 5488 - 5493. [Abstract] [Full Text]